TP53 and urinary bladder carcinoma: Moreover, researchers found that TP53, TTN and KMT2D had the highest mutation rates in bladder cancer, and TP53 could forecast the OS rate and treatment response of muscle-invasive BCa [49, 50], suggesting that TP53 gene might become a target of new drugs for BCa patients in the future.